Immunotherapeutic potential of collagen V oral administration in mBSA/CFA-induced arthritis.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2024
Historique:
received: 17 05 2024
accepted: 06 09 2024
medline: 8 10 2024
pubmed: 8 10 2024
entrez: 8 10 2024
Statut: epublish

Résumé

We hypothesized that after synovial injury, collagen V (Col V) expose occult antigens, and Col V autoantibodies develop, indicating the loss of immune tolerance against this molecule, thus leading to damage to mesenchymal-derived cells as well as the extracellular matrix in experimental arthritis. Thus, the present study investigated the effects of oral administration of Col V on the synovium after the development of inflammation in mBSA/CFA-induced arthritis. After fourteen days of intraarticular administration of mBSA, 10 male Lewis rats were orally administered Col V (500 μg/300 μL) diluted in 0.01 N acetic acid (IA-Col V group). The arthritic group (IA group, n = 10) received only intraarticular mBSA. An intra-articular saline injection (20 μL) was given to the control group (CT-Col V, n = 5). IA group presented damaged synovia, the expansion of the extracellular matrix by cellular infiltrate, which was characterized by T and B lymphocytes, and fibroblastic infiltration. In contrast, after Col V oral immunotherapy IA-Col V group showed a significant reduction in synovial inflammation and intense expression of IL-10+ and FoxP3+ cells, in addition to a reduction in Col V and an increase in Col I in the synovia compared to those in the IA group. Furthermore, an increase in IL-10 production was detected after IA-Col V group spleen cell stimulation with Col V in vitro. PET imaging did not differ between the groups. The evaluation of oral treatment with Col V, after mBSA/CFA-induced arthritis in rats, protects against inflammation and reduces synovial tissue damage, through modulation of the synovial matrix, showing an immunotherapeutic potential in inhibiting synovitis.

Identifiants

pubmed: 39378196
doi: 10.1371/journal.pone.0311263
pii: PONE-D-24-19996
doi:

Substances chimiques

Collagen Type V 0
Freund's Adjuvant 9007-81-2
methylated bovine serum albumin 0
Interleukin-10 130068-27-8
Forkhead Transcription Factors 0
Foxp3 protein, rat 0
Serum Albumin, Bovine 27432CM55Q

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0311263

Informations de copyright

Copyright: © 2024 Ramos da Silveira et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Auteurs

Lizandre Keren Ramos da Silveira (LK)

Division of Rheumatology, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, SP, Brazil.

Ana Paula P Velosa (APP)

Division of Rheumatology, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, SP, Brazil.

Sergio Catanozi (S)

Laboratorio de Lipides (LIM-10), Hospital das Clinicas (HCFMUSP) da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil.

Marco Aurélio A Pereira (MAA)

Department of Surgery, School of Veterinary Medicine and Animal Science, University of Sao Paulo, Sao Paulo, Brazil.

Antonio Dos Santos Filho (A)

Division of Rheumatology, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, SP, Brazil.

Fabio Luiz N Marques (FLN)

Laboratory of Nuclear Medicine (LIM 43), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.

Daniele de Paula Faria (D)

Laboratory of Nuclear Medicine (LIM 43), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.

Caroline Cristiano Real (CC)

Laboratory of Nuclear Medicine (LIM 43), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.

Sandra de M Fernezlian (SM)

Department of Pathology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, São Paulo, Brazil.

Amanda Flores Yanke (AF)

Division of Rheumatology, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, SP, Brazil.

Zelita Aparecida de J Queiroz (ZAJ)

Division of Rheumatology, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, SP, Brazil.

Vitória Elias Contini (VE)

Division of Rheumatology, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, SP, Brazil.

Thays de Matos Lobo (T)

Division of Rheumatology, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, SP, Brazil.

Solange Carrasco (S)

Division of Rheumatology, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, SP, Brazil.

Camila Machado Baldavira (CM)

Department of Pathology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, São Paulo, Brazil.

Cláudia Goldenstein-Schainberg (C)

Division of Rheumatology, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, SP, Brazil.

Ricardo Fuller (R)

Division of Rheumatology, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, SP, Brazil.

Vera L Capelozzi (VL)

Department of Pathology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, São Paulo, Brazil.

Walcy R Teodoro (WR)

Division of Rheumatology, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, SP, Brazil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH